Vera Therapeutics (VERA) Income from Continuing Operations (2020 - 2026)
Vera Therapeutics' (VERA) quarterly Income from Continuing Operations came in at 288249000.0 in Q1 2026, down 365.36% YoY from 108625401.14 in Q1 2025, and down 99.04% on a QoQ basis from 144821000.0 in Q4 2025.
Vera Therapeutics (VERA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Vera Therapeutics (VERA) has 7 years of Income from Continuing Operations data on file, last reported at 288249000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 365.36% year-over-year to 288249000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 607006000.0 (down 198.13% YoY) and the FY2025 annual result came in at 62919000.0, up 6292000.0% from the prior year.
- Income from Continuing Operations declined to 288249000.0 in Q1 2026, from 144821000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 17651000.0 in Q1 2022 to a low of 288249000.0 in Q1 2026.
- A 5-year average of 62771352.94 and a median of 38561000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations climbed 24.19% — and 2026, when it plunged 365.36%.
- Tracing VERA's Income from Continuing Operations over 5 years: stood at 33246000.0 in 2022, then retreated by 15.99% to 38561000.0 in 2023, then retreated by 14.42% to 44122000.0 in 2024, then sank by 228.23% to 144821000.0 in 2025, then slumped by 99.04% to 288249000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 288249000.0 (Q1 2026), 144821000.0 (Q4 2025), and 81420000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Vera Therapeutics | 2.28 Bn | 2.28 Bn | - | -294.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -294.29 Mn |
| Mar 31, 2026 | -288.25 Mn |
| Dec 31, 2025 | -144.82 Mn |
| Sep 30, 2025 | -81.42 Mn |
| Jun 30, 2025 | -92.52 Mn |
| Mar 31, 2025 | -61.94 Mn |
| Dec 31, 2024 | -44.12 Mn |
| Sep 30, 2024 | -53.00 Mn |
| Jun 30, 2024 | -44.55 Mn |
| Mar 31, 2024 | -33.50 Mn |
| Dec 31, 2023 | -38.56 Mn |
| Sep 30, 2023 | -25.26 Mn |
| Jun 30, 2023 | -21.01 Mn |
| Mar 31, 2023 | -30.51 Mn |
| Dec 31, 2022 | -33.25 Mn |
| Sep 30, 2022 | -33.32 Mn |
| Jun 30, 2022 | -23.44 Mn |
| Mar 31, 2022 | -17.65 Mn |
| Dec 31, 2021 | -16.58 Mn |
| Sep 30, 2021 | -7.25 Mn |